Rocket Pharmaceuticals, Inc. Other Operating Income (Expense), Net
Rocket Pharmaceuticals, Inc. (RCKT) reported Other Operating Income (Expense), Net of -$39.00 thousand for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherOperatingIncomeExpenseNet · last filed 2018-11-09
- Rocket Pharmaceuticals, Inc. other operating income (expense), net for the quarter ending 2018-09-30 was -$39.00K.
- Rocket Pharmaceuticals, Inc. other operating income (expense), net for the quarter ending 2018-06-30 was -$5.00K.
- Rocket Pharmaceuticals, Inc. other operating income (expense), net for the quarter ending 2017-09-30 was $0.00.
- Rocket Pharmaceuticals, Inc. other operating income (expense), net for the quarter ending 2017-06-30 was $0.00.
| Period end | Other Operating Income (Expense), Net 3 month | Other Operating Income (Expense), Net 6 month | Other Operating Income (Expense), Net 9 month |
|---|---|---|---|
| 2018-09-30 | -$39.00K 10-Q · filed 2018-11-09 | -$44.00K derived: sum of 2 quarters · filed 2018-11-09 | -$28.00K 10-Q · filed 2018-11-09 |
| 2018-06-30 | -$5.00K 10-Q · filed 2018-08-14 | $10.00K 10-Q · filed 2018-08-14 | |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-09 | $0.00 derived: sum of 2 quarters · filed 2018-11-09 | $0.00 10-Q · filed 2018-11-09 |
| 2017-06-30 | $0.00 10-Q · filed 2018-08-14 | $0.00 10-Q · filed 2018-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |